Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Abstract

Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 6
Figure 5
Figure 7

Similar content being viewed by others

References

  • Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB . (1996). Cancer Res., 56, 3087–3090.

  • Alarcon-Vargas D and Ronai Z . (2002). Carcinogenesis, 23, 541–547.

  • Ali-Osman F, Berger MS, Rajagopal S, Spence A and Livingston RB . (1993). Cancer Res., 53, 5663–5668.

  • Andrews PA, Murphy MP and Howell SB . (1987). Cancer Chemother. Pharmacol., 19, 149–154.

  • Andrews PA, Velury S, Mann SC and Howell SB . (1988). Cancer Res., 48, 68–73.

  • Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR and Brown R . (1996). Cancer Res., 56, 1374–1381.

  • Appella E and Anderson CW . (2001). Eur. J. Biochem., 268, 2764–2772.

  • Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD and Stewart SJ . (1994). Cancer Res., 54, 3758–3765.

  • Asselin E, Mills GB and Tsang BK . (2001). Cancer Res., 61, 1862–1868.

  • Baekelandt MM, Holm R, Nesland JM, Trope CG and Kristensen GB . (2000). Anticancer Res., 20, 1061–1067.

  • Bargmann CI, Hung MC and Weinberg RA . (1986). Nature, 319, 226–230.

  • Beale PJ, Rogers P, Boxall F, Sharp SY and Kelland LR . (2000). Br. J. Cancer, 82, 436–440.

  • Bellon SF, Coleman JH and Lippard SJ . (1991). Biochemistry, 30, 8026–8035.

  • Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt Jr D, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB and Kaufmann SH . (2000). Clin. Cancer Res., 6, 661–670.

  • Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, Jaggi R and Marti A . (2000). Cancer Res., 60, 4386–4390.

  • Borst P, Evers R, Kool M and Wijnholds J . (2000). J. Natl. Cancer Inst., 92, 1295–1302.

  • Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG and Anthoney DA . (1997). Oncogene, 15, 45–52.

  • Bullock AN and Fersht AR . (2001). Nat. Rev. Cancer, 1, 68–76.

  • Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O and Laurent-Puig P . (2000). J. Clin. Oncol., 18, 1465–1473.

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC . (1998). Science, 282, 1318–1321.

  • Chaney SG and Sancar A . (1996). J. Natl. Cancer Inst., 88, 1346–1360.

  • Chaney SG and Vaisman A . (1999). J. Inorg. Biochem., 77, 71–81.

  • Chao CC, Lee YL, Cheng PW and Lin-Chao S . (1991). Cancer Res., 51, 601–605.

  • Chiao C, Carothers AM, Grunberger D, Solomon G, Preston GA and Barrett JC . (1995). Cancer Res., 55, 3576–3583.

  • Chiba T, Takahashi S, Oguri-Hyakumachi N, Sahara H, Sato N and Kikuchi K . (1995). FASEB J., 9, A523.

  • Cocker HA, Hobbs SM, Tiffin N, Pritchard-Jones K, Pinkerton CR and Kelland LR . (2001). Br. J. Cancer, 85, 1746–1752.

  • Cui Y, Konig J, Buchholz JK, Spring H, Leier I and Keppler D . (1999). Mol. Pharmacol., 55, 929–937.

  • Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC and Persons DL . (2000). Mol. Carcinogen., 29, 219–228.

  • Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E . (1994). J. Clin. Invest., 94, 703–708.

  • Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'Incalci M and Broggini M . (2001). Neoplasia, 3, 10–16.

  • Daubeuf S, Leroy P, Paolicchi A, Pompella A, Wellman M, Galteau MM and Visvikis A . (2002). Biochem. Pharmacol., 64, 207–216.

  • del Bello B, Valentini MA, Zunino F, Comporti M and Maellaro E . (2001). Oncogene, 20, 4591–4595.

  • Delmastro DA, Li J, Vaisman A, Solle M and Chaney SG . (1997). Cancer Chemother. Pharmacol., 39, 245–253.

  • Demarcq C, Bunch RT, Creswell D and Eastman A . (1994). Cell Growth Differ., 5, 983–993.

  • Dempke W, Voigt W, Grothey A, Hill BT and Schmoll HJ . (2000). Anticancer Drugs, 11, 225–236.

  • Deng X, Kim M, Vandier D, Jung YJ, Rikiyama T, Sgagias MK, Goldsmith M and Cowan KH . (2002). Biochem. Biophys. Res. Commun., 296, 792–798.

  • Dent P and Grant S . (2001). Clin. Cancer Res., 7, 775–783.

  • D'Incalci M, Bonfanti M, Pifferi A, Mascellani E, Tagliabue G, Berger D and Fiebig HH . (1998). Eur. J. Cancer, 34, 1749–1755.

  • Donahue BA, Augot M, Bellon SF, Treiber DK, Toney JH, Lippard SJ and Essigmann JM . (1990). Biochemistry, 29, 5872–5880.

  • Drummond JT, Anthoney A, Brown R and Modrich P . (1996). J. Biol. Chem., 271, 19645–19648.

  • Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM and Modrich P . (1996). Proc. Natl. Acad. Sci. USA, 93, 6443–6447.

  • Eastman A . (1987a). Biochem. Pharmacol., 36, 4177–4178.

  • Eastman A . (1987b). Pharmacol. Ther., 34, 155–166.

  • Eastman A and Schulte N . (1988). Biochemistry, 27, 4730–4734.

  • Eastman A, Schulte N, Sheibani N and Sorenson CM . (1988). 178–196.

  • Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943.

  • Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.

    Google Scholar 

  • Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC and Young LS . (1995). Oncogene, 11, 1217–1228.

  • el Khateeb M, Appleton TG, Gahan LR, Charles BG, Berners-Price SJ and Bolton AM . (1999). J. Inorg. Biochem., 77, 13–21.

  • Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaine MA, Itzhaki M, Marty M and Extra JM . (1999). Ann. Oncol., 10, 1125–1128.

  • Fan J, Banerjee D, Stambrook PJ and Bertino JR . (1997). Biochem. Pharmacol., 53, 1203–1209.

  • Fan S, Chang JK, Smith ML, Duba D, Fornace Jr AJ and O'Connor PM . (1997). Oncogene, 14, 2127–2136.

  • Fan S, el Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace Jr AJ, Magrath I, Kohn KW and O'Connor PM . (1994). Cancer Res., 54, 5824–5830.

  • Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace Jr AJ and O'Connor PM . (1995). Cancer Res., 55, 1649–1654.

  • Farrow SN and Brown R . (1996). Curr. Opin. Genet. Dev., 6, 45–49.

  • Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM and Giaccone G . (2000). Clin. Cancer Res., 6, 203–212.

  • Ferry KV, Hamilton TC and Johnson SW . (2000). Biochem. Pharmacol., 60, 1305–1313.

  • Fink D, Aebi S and Howell SB . (1998). Clin. Cancer Res., 4, 1–6.

  • Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD and Howell SB . (1996). Cancer Res., 56, 4881–4886.

  • Fraval HN and Roberts JJ . (1979). Cancer Res., 39, 1793–1797.

  • Friedberg EC . (2001). Nat. Rev. Cancer, 1, 22–33.

  • Fritsche M, Haessler C and Brandner G . (1993). Oncogene, 8, 307–318.

  • Fuchs SY, Adler V, Pincus MR and Ronai Z . (1998). Proc. Natl. Acad. Sci. USA, 95, 10541–10546.

  • Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH and Pommier Y . (2002). Cancer Res., 62, 4899–4902.

  • Gallagher WM, Cairney M, Schott B, Roninson IB and Brown R . (1997). Oncogene, 14, 185–193.

  • Gately DP and Howell SB . (1993). Br. J. Cancer, 67, 1171–1176.

  • Gebauer G, Mirakhur B, Nguyen Q, Shore SK, Simpkins H and Dhanasekaran N . (2000). Int. J. Oncol., 16, 321–325.

  • Giaccone G . (2000). Drugs, 59 (Suppl 4), 9–17.

  • Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME . (1992). Proc. Natl. Acad. Sci. USA, 89, 3070–3074.

  • Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M and Wang JY . (1999). Nature, 399, 806–809.

  • Gore M, Fryatt I, Wiltshaw E, Dawson T, Robinson B and Calvert A . (1989). Br. J. Cancer, 60, 767–769.

  • Goto S, Iida T, Cho S, Oka M, Kohno S and Kondo T . (1999). Free Radical Res., 31, 549–558.

  • Gottlieb TM, Leal JF, Seger R, Taya Y and Oren M . (2002). Oncogene, 21, 1299–1303.

  • Gowen LC, Avrutskaya AV, Latour AM, Koller BH and Leadon SA . (1998). Science, 281, 1009–1012.

  • Hagopian GS, Mills GB, Khokhar AR, Bast Jr RC and Siddik ZH . (1999). Clin. Cancer Res., 5, 655–663.

  • Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF and Hamilton TC . (1993). Cancer Res., 53, 5225–5232.

  • Hanahan D and Weinberg RA . (2000). Cell, 100, 57–70.

  • Hartwell LH and Kastan MB . (1994). Science, 266, 1821–1828.

  • Hawkins DS, Demers GW and Galloway DA . (1996). Cancer Res., 56, 892–898.

  • Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y . (2000). Cancer Res., 60, 5988–5994.

  • He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.

  • He Q, Liang CH and Lippard SJ . (2000). Proc. Natl. Acad. Sci. USA, 97, 5768–5772.

  • Heiger-Bernays WJ, Essigmann JM and Lippard SJ . (1990). Biochemistry, 29, 8461–8466.

  • Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F and Tanner B . (1999). Cancer Res., 59, 3206–3214.

  • Henkels KM and Turchi JJ . (1997). Cancer Res., 57, 4488–4492.

  • Henkels KM and Turchi JJ . (1999). Cancer Res., 59, 3077–3083.

  • Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ . (1996). Cancer Res., 56, 2178–2184.

  • Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL and Johnson CS . (2002). Mol. Cancer Ther., 1, 821–829.

  • Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP and Harrap KR . (1989). Br. J. Cancer, 59, 527–534.

  • Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL and Korsmeyer SJ . (1993). Cell, 75, 241–251.

  • Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100.

  • Hollstein M, Sidransky D, Vogelstein B and Harris CC . (1991). Science, 253, 49–53.

  • Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ and Chaganti RS . (1998). Oncogene, 16, 2345–2349.

  • Huang JC, Zamble DB, Reardon JT, Lippard SJ and Sancar A . (1994). Proc. Natl. Acad. Sci. USA, 91, 10394–10398.

  • Hung MC and Lau YK . (1999). Semin. Oncol., 26, 51–59.

  • Husain A, He G, Venkatraman ES and Spriggs DR . (1998). Cancer Res., 58, 1120–1123.

  • Ikeguchi M, Liu J and Kaibara N . (2002). Apoptosis, 7, 23–29.

  • Izquierdo MA, van der Zee AG, Vermorken JB, van d V, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM and Kenemans P . (1995). J. Natl. Cancer Inst., 87, 1230–1237.

  • Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M and Prives C . (1998). Genes Dev., 12, 462–472.

  • Jennerwein MM, Eastman A and Khokhar A . (1989). Chem. Biol. Interact., 70, 39–49.

  • Jennerwein MM, Eastman A and Khokhar AR . (1991). Mutat. Res., 254, 89–96.

  • Johnson SW, Laub PB, Beesley JS, Ozols RF and Hamilton TC . (1997). Cancer Res., 57, 850–856.

  • Jordan P and Carmo-Fonseca M . (2000). Cell Mol. Life Sci., 57, 1229–1235.

  • Kartalou M and Essigmann JM . (2001). Mutat. Res., 478, 23–43.

  • Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T and Saijo N . (1991). Cancer Res., 51, 3237–3242.

  • Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW . (1991). Cancer Res., 51, 6304–6311.

  • Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M and Howell SB . (2002). Cancer Res., 62, 6559–6565.

  • Kelland LR . (1993). Crit. Rev. Oncol. Hematol., 15, 191–219.

  • Kelland LR . (2000). Drugs, 59 (Suppl 4), 1–8.

  • Kelland LR, Barnard CF, Evans IG, Murrer BA, Theobald BR, Wyer SB, Goddard PM, Jones M, Valenti M and Bryant A . (1995). J. Med. Chem., 38, 3016–3024.

  • Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ and Harrap KR . (1992a). Cancer Res., 52, 1710–1716.

  • Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA and Harrap KR . (1992b). Cancer Res., 52, 3857–3864.

  • Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ and Judson IR . (1999). J. Inorg. Biochem., 77, 111–115.

  • Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS . (1988). Science, 241, 1813–1815.

  • Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L and Cho KR . (1993). Proc. Natl. Acad. Sci. USA, 90, 3988–3992.

  • Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan ZM, Ghanem L, Rana A, Weichselbaum R, Johnson G and Kufe D . (2000). Mol. Cell. Biol., 20, 4979–4989.

  • Koberle B, Masters JR, Hartley JA and Wood RD . (1999). Curr. Biol., 9, 273–276.

  • Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M and Kuwano M . (1997). Cancer Res., 57, 5475–5479.

  • Kolfschoten GM, Pinedo HM, Scheffer PG, Schluper HM, Erkelens CA and Boven E . (2000). Gynecol. Oncol., 76, 362–368.

  • Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T and Akiyama S . (2000). Cancer Res., 60, 1312–1316.

  • Kondo S, Barnett GH, Hara H, Morimura T and Takeuchi J . (1995). Oncogene, 10, 2001–2006.

  • Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P . (1997). Cancer Res., 57, 3537–3547.

  • Lai GM, Ozols RF, Smyth JF, Young RC and Hamilton TC . (1988). Biochem. Pharmacol., 37, 4597–4600.

  • Lakin ND and Jackson SP . (1999). Oncogene, 18, 7644–7655.

  • Larminat F and Bohr VA . (1994). Nucleic Acids Res., 22, 3005–3010.

  • Lee KB, Parker RJ, Bohr V, Cornelison T and Reed E . (1993). Carcinogenesis, 14, 2177–2180.

  • Leppa S and Bohmann D . (1999). Oncogene, 18, 6158–6162.

  • Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD and Howell SB . (2001). Cancer Res., 61, 1508–1516.

  • Lin X, Ramamurthi K, Mishima M, Kondo A and Howell SB . (2000). Mol. Pharmacol., 58, 1222–1229.

  • Makin GW, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA and Dive C . (2001). EMBO J., 20, 6306–6315.

  • Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL and Chaney SG . (1994). Cancer Res., 54, 3500–3505.

  • Mandic A, Viktorsson K, Heiden T, Hansson J and Shoshan MC . (2001). Melanoma Res., 11, 11–19.

  • Martin-Blanco E . (2000). BioEssays, 22, 637–645.

  • Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W and Schauer A . (1998). Eur. J. Cancer, 34, 845–850.

  • Mayer F, Gillis AJ, Dinjens W, Oosterhuis JW, Bokemeyer C and Looijenga LH . (2002). Cancer Res., 62, 2758–2760.

  • Mayo LD and Donner DB . (2002). Trends Biochem. Sci., 27, 462–467.

  • Meek DW . (1999). Oncogene, 18, 7666–7675.

  • Mello JA, Acharya S, Fishel R and Essigmann JM . (1996). Chem. Biol., 3, 579–589.

  • Micheau O, Solary E, Hammann A, Martin F and Dimanche-Boitrel MT . (1997). J. Natl. Cancer Inst., 89, 783–789.

  • Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR . (1991). Br. J. Cancer, 64, 215–220.

  • Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC and Testa JR . (2000). Cancer Res., 60, 5390–5394.

  • Miyake H, Hara I, Yamanaka K, Arakawa S and Kamidono S . (1999). J. Urol., 162, 2176–2181.

  • Morgan SE and Kastan MB . (1997). Adv. Cancer Res., 71, 1–25.

  • Mossink MH, Van Zon A, Franzel-Luiten E, Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P and Wiemer EA . (2002). Cancer Res., 62, 7298–7304.

  • Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M and Krammer PH . (1998). J. Exp. Med., 188, 2033–2045.

  • Murphy D, McGown AT, Crowther D, Mander A and Fox BW . (1991). Br. J. Cancer, 63, 711–714.

  • Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, Izumi H, Makishima K and Kohno K . (2001). Cancer Res., 61, 1592–1597.

  • Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N and Takebayashi Y . (2002). Int. J. Cancer, 101, 488–495.

  • Nehme A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JY, Howell SB and Christen RD . (1997). Cancer Res., 57, 3253–3257.

  • O'Connor PM and Fan S . (1996). Prog. Cell Cycle Res., 2, 165–173.

  • O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ and Kohn KW . (1997). Cancer Res., 57, 4285–4300.

  • Ono Y, Nonomura N, Harada Y, Fukui T, Tokizane T, Sato E, Nakayama M, Nishimura K, Takahara S and Okuyama A . (2001). Mol. Urol., 5, 25–30.

  • Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y and Ben-Ze'Ev A . (2002). Ann. N.Y. Acad. Sci., 973, 374–383.

  • Ormerod MG, O'Neill C, Robertson D, Kelland LR and Harrap KR . (1996). Cancer Chemother. Pharmacol., 37, 463–471.

  • Ozols RF . (1991). Cancer Treat. Rev., 18 (Suppl A), 77–83.

  • Ozols RF . (1992). Hematol. Oncol. Clin. N. Am., 6, 879–894.

  • Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y and Young RC . (1984). Ann. Intern. Med., 100, 19–24.

  • Ozols RF, Hamilton TC, Reed E, Poirier MC, Masuda H, Lai G and Young RC . (1988). Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Nicolini M (ed). Martinus Nijhoff: Boston, pp. 197–206.

    Book  Google Scholar 

  • Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC and O'Dwyer PJ . (2002). Biochem. Pharmacol., 63, 1699–1707.

  • Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F . (1996). Cancer Res., 56, 556–562.

  • Persons DL, Yazlovitskaya EM and Pelling JC . (2000). J. Biol. Chem., 275, 35778–35785.

  • Pietenpol JA, Tokino T, Thiagalingam S, el Deiry WS, Kinzler KW and Vogelstein B . (1994). Proc. Natl. Acad. Sci. USA, 91, 1998–2002.

  • Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB and Slamon DJ . (1994). Oncogene, 9, 1829–1838.

  • Pinto AL and Lippard SJ . (1985). Biochim. Biophys. Acta, 780, 167–180.

  • Prestayko AW, D'Aoust JC, Issell BF and Crooke ST . (1979). Cancer Treat. Rev., 6, 17–39.

  • Qin LF and Ng IO . (2002). Cancer Lett., 175, 27–38.

  • Reed E . (1998). Cancer Treat. Rev., 24, 331–344.

  • Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.

  • Richon VM, Schulte N and Eastman A . (1987). Cancer Res., 47, 2056–2061.

  • Righetti SC, Della TG, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F . (1996). Cancer Res., 56, 689–693.

  • Righetti SC, Perego P, Corna E, Pierotti MA and Zunino F . (1999). Cell Growth Differ., 10, 473–478.

  • Roberts JJ and Fraval HN . (1980). Cisplatin: Current Status and New Developments. Prestayko AW, Crooke ST and Carter SK (eds). Academic Press: Orlando, pp. 57–77.

    Book  Google Scholar 

  • Roberts JJ and Pera Jr JJ . (1983). Platinum, Gold, and other Metal Chemotherapeutic Agents: Chemistry and Biochemistry. Lippard SJ (ed). American Chemical Society: Washington, DC, pp. 3–25.

    Book  Google Scholar 

  • Robinson MJ and Cobb MH . (1997). Curr. Opin. Cell Biol., 9, 180–186.

  • Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, Ochiai K, Tanaka T, Kikuchi Y and Tenjin Y . (2001). Hum. Cell, 14, 305–315.

  • Sancar A . (1994). Science, 266, 1954–1956.

  • Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM and Gutkind JS . (2002). Oncogene, 21, 974–979.

  • Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C and Scher HI . (1995). J. Clin. Oncol., 13, 1384–1390.

  • Scherer SJ, Welter C, Zang KD and Dooley S . (1996). Biochem. Biophys. Res. Commun., 221, 722–728.

  • Schilder RJ, Hall L, Monks A, Handel LM, Fornace Jr AJ, Ozols RF, Fojo AT and Hamilton TC . (1990). Int. J. Cancer, 45, 416–422.

  • Schilder RJ and Ozols RF . (1992). Cancer Invest., 10, 307–315.

  • Schmidt W and Chaney SG . (1993). Cancer Res., 53, 799–805.

  • Schuler M and Green DR . (2001). Biochem. Soc. Trans., 29, 684–688.

  • Segal-Bendirdjian E, Mannone L and Jacquemin-Sablon A . (1998). Cell Death Differ., 5, 390–400.

  • Shah MA and Schwartz GK . (2001). Clin. Cancer Res., 7, 2168–2181.

  • Shapiro GI, Edwards CD, Ewen ME and Rollins BJ . (1998). Mol. Cell. Biol., 18, 378–387.

  • Shapiro GI and Harper JW . (1999). J. Clin. Invest., 104, 1645–1653.

  • Sheibani N, Jennerwein MM and Eastman A . (1989). Biochemistry, 28, 3120–3124.

  • Shen DW, Goldenberg S, Pastan I and Gottesman MM . (2000). J. Cell. Physiol., 183, 108–116.

  • Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW and Greenberg AH . (1994). Science, 263, 1143–1145.

  • Shieh SY, Ahn J, Tamai K, Taya Y and Prives C . (2000). Genes Dev., 14, 289–300.

  • Shieh SY, Ikeda M, Taya Y and Prives C . (1997). Cell, 91, 325–334.

  • Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M and Cullen KJ . (1999). Clin. Cancer Res., 5, 4097–4104.

  • Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T and Khokhar AR . (1999). J. Inorg. Biochem., 77, 65–70.

  • Siddik ZH, Mims B, Lozano G and Thai G . (1998). Cancer Res., 58, 698–703.

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A . (1989). Science, 244, 707–712.

  • Slater AF, Nobel CS, Maellaro E, Bustamante J, Kimland M and Orrenius S . (1995). Biochem. J., 306 (Part 3), 771–778.

  • Smith CD, Carmeli S, Moore RE and Patterson GM . (1993). Cancer Res., 53, 1343–1347.

  • Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM and Fornace Jr AJ . (1994). Science, 266, 1376–1380.

  • Smith ML, Kontny HU, Bortnick R and Fornace Jr AJ . (1997). Exp. Cell Res., 230, 61–68.

  • Sorenson CM and Eastman A . (1988). Cancer Res., 48, 6703–6707.

  • Soussi T . (2000). Ann. N.Y. Acad. Sci., 910, 121–137.

  • Strasser A, Harris AW, Jacks T and Cory S . (1994). Cell, 79, 329–339.

  • Svejstrup JQ . (2002). Nat. Rev. Mol. Cell Biol., 3, 21–29.

  • Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW and Ingram AJ . (2002). J. Biol. Chem., 277, 12710–12717.

  • Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT and Frei III E . (1991). Int. J. Cancer, 47, 252–260.

  • Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD and Frei III E . (1987). Cancer Res., 47, 388–393.

  • Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK and Hung MC . (1995). J. Natl. Cancer Inst., 87, 682–684.

  • Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC and Chaney SG . (1998). Cancer Res., 58, 3579–3585.

  • van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG and de Vries EG . (1995). J. Clin. Oncol., 13, 70–78.

  • Van't Veer LJ, Hermens R, van den Berg-Bakker LA, Cheng NC, Fleuren GJ, Bos JL, Cleton FJ and Schrier PI . (1988). Oncogene, 2, 157–165.

  • Wada H, Saikawa Y, Niida Y, Nishimura R, Noguchi T, Matsukawa H, Ichihara T and Koizumi S . (1999). Exp. Hematol., 27, 99–109.

  • Wang X, Martindale JL and Holbrook NJ . (2000). J. Biol. Chem., 275, 39435–39443.

  • Woessmann W, Chen X and Borkhardt A . (2002). Cancer Chemother. Pharmacol., 50, 397–404.

  • Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, Adams DJ, Lewis AD, Scott AR and Smyth JF . (1987). Int. J. Cancer, 39, 695–702.

  • Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K . (1986). Nature, 319, 230–234.

  • Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK and Cheng AL . (2002). Biochem. Pharmacol., 63, 1423–1430.

  • Yoshida M, Khokhar AR and Siddik ZH . (1994). Cancer Res., 54, 3468–3473.

  • Yoshida M, Khokhar AR and Siddik ZH . (1998). Oncol. Rep., 5, 1281–1287.

  • Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM and Marinus MG . (2002). J. Biol. Chem., 277, 1255–1260.

  • Zhang L and Hung MC . (1996). Oncogene, 12, 571–576.

  • Zhang Y, Ma WY, Kaji A, Bode AM and Dong Z . (2002). J. Biol. Chem., 277, 3124–3131.

  • Zhao H and Piwnica-Worms H . (2001). Mol. Cell. Biol., 21, 4129–4139.

  • Zhou BP and Hung MC . (2002). Semin. Oncol., 29, 62–70.

  • Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC . (2001). Nat. Cell Biol., 3, 245–252.

Download references

Acknowledgements

This work was supported by NIH Grants CA77332 and CA82361, and US Army Grant DAMD 17-99-1-9269. I sincerely thank Kay Biescar for her assistance in preparing this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zahid H Siddik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siddik, Z. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265–7279 (2003). https://doi.org/10.1038/sj.onc.1206933

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206933

Keywords

This article is cited by

Search

Quick links